Immutep: Reports positive interim data for cancer therapy
- Biotech company Immutep (IMM) has put out some promising interim results from its phase two study of a new cancer therapy
- Patients are receiving efti in concert with Merck & Co’s Keytruda (pembrolizumab) therapy
- Immutep CSO and CMO Dr Frederic Triebel says the results are very encouraging
- Tumour shrinkage and overall response rates are also showing positive results
- Data gathering also will continue as more patients are enrolled and existing patients are monitored
- Immutep is still in a trading halt related to this announcement — shares are currently worth 17.5 cents each
